317 related articles for article (PubMed ID: 33085221)
1. Projected Utility of Pharmacogenomic Testing Among Individuals Hospitalized With COVID-19: A Retrospective Multicenter Study in the United States.
Stevenson JM; Alexander GC; Palamuttam N; Mehta HB
Clin Transl Sci; 2021 Jan; 14(1):153-162. PubMed ID: 33085221
[TBL] [Abstract][Full Text] [Related]
2. An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes.
Mostafa S; Kirkpatrick CMJ; Byron K; Sheffield L
J Neural Transm (Vienna); 2019 Jan; 126(1):5-18. PubMed ID: 30191366
[TBL] [Abstract][Full Text] [Related]
3. Assessing Clinical Utility of Pharmacogenetic Testing in the Military Health System.
Hellwig LD; Turner C; Olsen C; Libbus J; Markos B; Koehlmoos T; Haigney M; De Castro M; Saunders D
Mil Med; 2024 Jan; 189(1-2):e198-e204. PubMed ID: 37436924
[TBL] [Abstract][Full Text] [Related]
4. Development of the PGx-Passport: A Panel of Actionable Germline Genetic Variants for Pre-Emptive Pharmacogenetic Testing.
van der Wouden CH; van Rhenen MH; Jama WOM; Ingelman-Sundberg M; Lauschke VM; Konta L; Schwab M; Swen JJ; Guchelaar HJ
Clin Pharmacol Ther; 2019 Oct; 106(4):866-873. PubMed ID: 31038729
[TBL] [Abstract][Full Text] [Related]
5. Retrospective Review of Pharmacogenetic Testing at an Academic Children's Hospital.
Roberts TA; Wagner JA; Sandritter T; Black BT; Gaedigk A; Stancil SL
Clin Transl Sci; 2021 Jan; 14(1):412-421. PubMed ID: 33048453
[TBL] [Abstract][Full Text] [Related]
6. Projected impact of pharmacogenomic testing on medications beyond antiplatelet therapy in percutaneous coronary intervention patients.
Black RM; Williams AK; Ratner L; Crona DJ; Wiltshire T; Weck KE; Stouffer GA; Lee CR
Pharmacogenomics; 2020 May; 21(7):431-441. PubMed ID: 32343201
[No Abstract] [Full Text] [Related]
7. Preemptive Pharmacogenomic Testing for Precision Medicine: A Comprehensive Analysis of Five Actionable Pharmacogenomic Genes Using Next-Generation DNA Sequencing and a Customized CYP2D6 Genotyping Cascade.
Ji Y; Skierka JM; Blommel JH; Moore BE; VanCuyk DL; Bruflat JK; Peterson LM; Veldhuizen TL; Fadra N; Peterson SE; Lagerstedt SA; Train LJ; Baudhuin LM; Klee EW; Ferber MJ; Bielinski SJ; Caraballo PJ; Weinshilboum RM; Black JL
J Mol Diagn; 2016 May; 18(3):438-445. PubMed ID: 26947514
[TBL] [Abstract][Full Text] [Related]
8. Fetal pharmacogenomics: A promising addition to complex neonatal care.
Raymond M; Critchlow E; Rice SM; Wodoslawsky S; Berger SI; Hegde M; Empey PE; Al-Kouatly HB
Mol Genet Metab; 2022; 137(1-2):140-145. PubMed ID: 36029725
[TBL] [Abstract][Full Text] [Related]
9. Nine-gene pharmacogenomics profile service: The Mayo Clinic experience.
Matey ET; Ragan AK; Oyen LJ; Vitek CR; Aoudia SL; Ragab AK; Fee-Schroeder KC; Black JL; Moyer AM; Nicholson WT; Shrestha S; McAllister TM; Sinnwell JP; Faubion SS; Lazaridis KN
Pharmacogenomics J; 2022 Feb; 22(1):69-74. PubMed ID: 34671112
[TBL] [Abstract][Full Text] [Related]
10. Description of Pharmacogenomic Testing Among Patients Admitted to the Intensive Care Unit After Cardiovascular Surgery.
Peterson PE; Nicholson WT; Moyer AM; Arendt CJ; Smischney NJ; Seelhammer TG; Krecke CA; Haney RM; Yaw EJ; Chlan LL
J Intensive Care Med; 2021 Nov; 36(11):1281-1285. PubMed ID: 32734840
[TBL] [Abstract][Full Text] [Related]
11. Prescribing Prevalence of Medications With Potential Genotype-Guided Dosing in Pediatric Patients.
Ramsey LB; Ong HH; Schildcrout JS; Shi Y; Tang LA; Hicks JK; El Rouby N; Cavallari LH; Tuteja S; Aquilante CL; Beitelshees AL; Lemkin DL; Blake KV; Williams H; Cimino JJ; Davis BH; Limdi NA; Empey PE; Horvat CM; Kao DP; Lipori GP; Rosenman MB; Skaar TC; Teal E; Winterstein AG; Owusu Obeng A; Salyakina D; Gupta A; Gruber J; McCafferty-Fernandez J; Bishop JR; Rivers Z; Benner A; Tamraz B; Long-Boyle J; Peterson JF; Van Driest SL;
JAMA Netw Open; 2020 Dec; 3(12):e2029411. PubMed ID: 33315113
[TBL] [Abstract][Full Text] [Related]
12. Identification of high-impact gene-drug pairs for pharmacogenetic testing in Alberta, Canada.
Fan M; Yarema MC; Box A; Hume S; Aitchison KJ; Bousman CA
Pharmacogenet Genomics; 2021 Feb; 31(2):29-39. PubMed ID: 32826605
[TBL] [Abstract][Full Text] [Related]
13. Review and Consensus on Pharmacogenomic Testing in Psychiatry.
Bousman CA; Bengesser SA; Aitchison KJ; Amare AT; Aschauer H; Baune BT; Asl BB; Bishop JR; Burmeister M; Chaumette B; Chen LS; Cordner ZA; Deckert J; Degenhardt F; DeLisi LE; Folkersen L; Kennedy JL; Klein TE; McClay JL; McMahon FJ; Musil R; Saccone NL; Sangkuhl K; Stowe RM; Tan EC; Tiwari AK; Zai CC; Zai G; Zhang J; Gaedigk A; Müller DJ
Pharmacopsychiatry; 2021 Jan; 54(1):5-17. PubMed ID: 33147643
[TBL] [Abstract][Full Text] [Related]
14. Assessment of the Implementation of Pharmacogenomic Testing in a Pediatric Tertiary Care Setting.
Cohn I; Manshaei R; Liston E; Okello JBA; Khan R; Curtis MR; Krupski AJ; Jobling RK; Kalbfleisch K; Paton TA; Reuter MS; Hayeems RZ; Verstegen RHJ; Goldman A; Kim RH; Ito S
JAMA Netw Open; 2021 May; 4(5):e2110446. PubMed ID: 34037732
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenomic prescribing opportunities in percutaneous coronary intervention and bone marrow transplant patients.
Ratner L; Zhu J'; Gower MN; Patel T; Miller JA; Cipriani A; Stouffer GA; Crona DJ; Lee CR
Pharmacogenomics; 2022 Feb; 23(3):183-194. PubMed ID: 35083934
[No Abstract] [Full Text] [Related]
16.
Forbes M; Hopwood M; Bousman CA
Genes (Basel); 2023 Oct; 14(10):. PubMed ID: 37895294
[TBL] [Abstract][Full Text] [Related]
17. Comparison of targeted vs. expanded pharmacogenomic testing: What are we missing?
Chambal M; Forsthoffer C; Egnaczyk A; Seitz M; Grande K; Ashcraft K; Wick JA; Blaxall BC
J Am Pharm Assoc (2003); 2023; 63(3):939-945. PubMed ID: 37024375
[TBL] [Abstract][Full Text] [Related]
18. Determining the potential clinical value of panel-based pharmacogenetic testing in patients with chronic pain or gastroesophageal reflux disease.
Elchynski AL; Cicali EJ; Ferrer Del Busto MC; Hamilton A; Chang KL; Schmidt SO; Weiner B; Davis R; Estores D; Max Smith D; Wiisanen K; Johnson JA; Cavallari LH
Pharmacogenomics J; 2021 Dec; 21(6):657-663. PubMed ID: 34075203
[TBL] [Abstract][Full Text] [Related]
19. Projected impact of a multigene pharmacogenetic test to optimize medication prescribing in cardiovascular patients.
Dong OM; Li A; Suzuki O; Oni-Orisan A; Gonzalez R; Stouffer GA; Lee CR; Wiltshire T
Pharmacogenomics; 2018 Jun; 19(9):771-782. PubMed ID: 29793377
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenomics implementation in cardiovascular disease in a highly diverse population: initial findings and lessons learned from a pilot study in United Arab Emirates.
Al-Mahayri ZN; Khasawneh LQ; Alqasrawi MN; Altoum SM; Jamil G; Badawi S; Hamza D; George L; AlZaabi A; Ouda H; Al-Maskari F; AlKaabi J; Patrinos GP; Ali BR
Hum Genomics; 2022 Sep; 16(1):42. PubMed ID: 36154845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
